Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study
|ClinicalTrials.gov Identifier: NCT01133080|
Recruitment Status : Unknown
Verified January 2012 by Shalvata Mental Health Center.
Recruitment status was: Recruiting
First Posted : May 28, 2010
Last Update Posted : January 5, 2012
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Minocycline Drug: placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||June 2010|
|Estimated Primary Completion Date :||January 2013|
|Estimated Study Completion Date :||January 2013|
minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
|Placebo Comparator: Placebo||
placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.
From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
- Positive symptoms [ Time Frame: from baseline to the end of the study (day 56) ]Positive symptoms: The change in Scale for the Positive and Negative Syndrome Scale (PANSS) score from baseline to the end of the study and the change in Clinical Global Impression Scale (CGI).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01133080
|Contact: yechiel levkovitz, MD, PhDfirstname.lastname@example.org|
|Shalvata Mental Health Center||Recruiting|
|Hod Hasharon, Israel|
|Contact: Hilik Levkovitz, prof. 972-9-7478644 email@example.com|
|shalvata MHC||Not yet recruiting|
|Hod HAsharon, Israel|
|Contact: yechiel levkovitz 972-9-7478644|
|Principal Investigator: yechiel levkovitz, MD, PhD|
|Principal Investigator:||Yechiel Levkovitz, MD, PhD||Shalvata MHC|